Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 9:21:722-6.
doi: 10.12659/MSM.893213.

Expression and significance of circulating microRNA-31 in lung cancer patients

Hai-Jun Yan  1 , Ji-Yong Ma  1 , Li Wang  1 , Wei Gu  1
Affiliations

Expression and significance of circulating microRNA-31 in lung cancer patients

Hai-Jun Yan et al. Med Sci Monit. .

Abstract

Background: The aim of this study was to investigate the expression level of circulating microRNA-31(miRNA-31) in lung cancer patients and its clinical significance.

Material and methods: Real-time fluorescent quantitative PCR was utilized to detect the circulating miRNA-31 expression levels in 300 lung cancer patients and 300 health control subjects. The ROC curve was drawn to evaluate the diagnostic value of the circulating miRNA-31 expression levels in lung cancer. The 300 lung cancer patients were divided into a miRNA-31 low-expression group and a miRNA-31 high-expression group. A survival curve was drawn according to the Kaplan-Meier method to evaluate the prognostic value of the circulating microRNA-31 expression levels for lung cancer.

Results: The circulating miRNA-31 expression levels in the lung cancer patients (l.88±0. 67) increased significantly (P<0.001) compared to the healthy controls (0.58±0. 44). The area under the ROC curve drawn according to the circulating miRNA-31 expression levels was 0.785 (95% CI=0.486-0.763). When the critical value was 1.27, the sensitivity and specificity for lung cancer diagnosis according to the circulating miRNA-31 expression levels were 0.769 and 0.745, respectively. The difference in the survival curve between the miRNA-31 low-expression group (123 cases) and high-expression group (177 cases) was statistically significant (P=0.004). Median survival period of the low-expression group (38.44 months) was longer than that of the high-expression group (25.23 months).

Conclusions: miRNA-31 may be a molecular marker for the diagnostic and prognostic evaluation of primary lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
ROC curve for expression of circulating miRNA-31 levels in lung cancer, with an area under the ROC curve=0.785.
Figure 2
Figure 2
Kaplan-Meier analysis curve of postoperative survival times of lung cancer patients according to the miRNA-31 relative expression. Patients with high miRNA-31 expression had significantly poorer survival times compared to those with low miRNA-31 expression. P values were calculated by Kaplan-Meier analysis (P<0.001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sheel AR, McShane J, Poullis MP. Survival of patients with or without symptoms undergoing potentially curative resections for primary lung cancer. Ann Thorac Surg. 2013;95(1):276–84. - PubMed
    1. Del Vescovo V, Grasso M, Barbareschi M, Denti MA. MicroRNAs as lung cancer biomarkers. World J Clin Oncol. 2014;5(4):604–20. - PMC - PubMed
    1. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis. 2013;2:e40. - PMC - PubMed
    1. Creighton CJ, Fountain MD, Yu Z, et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. Cancer Res. 2010;70:1906–15. - PMC - PubMed
    1. Valastyan S, Reinhardt F, Benaich N, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 2009;137:1032–46. - PMC - PubMed

Publication types